OMC
DNLI icon

Old Mission Capital’s Denali Therapeutics DNLI Stock Holding History

Old Mission Capital’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-15,522
Closed -$783K – 1072
2021
Q3 		$783K Buy
+15,522
New +$875K 0.03% 452

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Old Mission Capital's DNLI Position: Q4 2021 in Review

Old Mission Capital sold out of Denali Therapeutics (DNLI) in Q4 2021, closing a stake of 15,522 shares — an estimated $783K sold.

Old Mission Capital first reported a position in DNLI in Q3 2021 and held it in 1 quarter. The position peaked at $783K in Q3 2021. 213 funds tracked by Wall St. Rank hold DNLI as of Q4 2021.

  • Old Mission Capital reported no remaining Denali Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Old Mission Capital sold 15,522 Denali Therapeutics shares in Q4 2021, an estimated $783K.
  • Old Mission Capital first reported a position in Denali Therapeutics in Q3 2021 and held it in 1 quarter.
  • Old Mission Capital's Denali Therapeutics position peaked at $783K in Q3 2021.
  • 213 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2021.

Based on Old Mission Capital's 13F filing for Q4 2021, filed 10 Feb 2022.